JAMA

10/10/2026

: Approximately 1 in 5 Americans live in rural areas, and upcoming changes under the One Big Beautiful Bill Act may substantially reshape their health care options.

🎙️ In this episode of Healthy Dialogue, JAMA Senior Editor Derek C. Angus, MD, MPH, spoke with Julie Donohue, PhD, and Mark Holmes, PhD, about Medicaid cuts, the $50 billion Rural Health Transformation Program, and what these policies may mean for access and local care delivery.

Rural health care in the US is discussed by JAMA Senior Editor Derek C. Angus, MD, MPH; Mark Holmes, PhD, director of The Cecil G. Sheps Center for Health Services Research at The University of North Carolina at Chapel Hill; and Julie Donohue, PhD, professor and chair of health policy and management...

10/10/2026

Among patients with early , treatment with nicotinamide riboside for 52 weeks did not improve clinical outcomes vs placebo and was associated with worse change in overall Movement Disorder Society Unified Parkinson Disease Rating Scale scores.

These findings do not support nicotinamide riboside as a disease-modifying treatment for Parkinson disease.

https://ja.ma/4hVxsVu

10/10/2026

📣 JAMA and the JAMA Network journals are issuing a call for papers on .

Last year, we launched JAMA+ Women's Health, an initiative that offers expertly curated research and insights from work published in JAMA and the JAMA Network. An important goal of JAMA+ Women's Health is to shift the conversation about women’s health beyond the “usual” categories of , , , and certain .

To align with the 2027 International Women’s Day, JAMA and the JAMA Network journals will publish women’s health articles across the full spectrum of health care on March 8, 2027.

This call for papers will prioritize timely and novel research articles and opinion manuscripts. Manuscripts submitted by November 15, 2026, will have the best chance for consideration for simultaneous publication on International Women’s Day.

🔗 Read the full editorial: https://ja.ma/47GKukL

10/10/2026

Among Black and White older adults with serious illness, a facilitated approach did not result in significantly different 1-year advance care planning completion than a self-guided approach within either racial group.

Completion was common in both groups, indicating that multiple lay facilitator–supported approaches may support advance care planning participation in real-world primary care and geriatrics settings.

https://ja.ma/478azsP

10/10/2026

Among medically underserved adults referred for screening with low-dose computed tomography, adding financial incentives to ask-advise-refer and free smoking cessation pharmacotherapy was associated with higher biochemically confirmed sustained to***co abstinence through 6 months.

Free pharmacotherapy alone was not superior to ask-advise-refer, and adding a text-based future health tool did not improve outcomes beyond incentives.

https://ja.ma/4zhg0Sl

10/10/2026

In this podcast, JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, and Deputy Editor Preeti Malani, MD, MSJ, discussed the latest science published in JAMA:

➡️ Incentives for Cessation in Underserved ,
➡️ Riboside for Disease,
➡️ Advanced ,
➡️ -Related by Occupation, and more.

🎧 Listen now:

Editor’s Summary by Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief, and Preeti Malani, MD, MSJ, Deputy Editor of JAMA, the Journal of the American Medical Association, for articles published from October 3-9, 2026.

10/10/2026

Among working-age adults in the US, mortality varied substantially by occupation and industry, with the highest rates in military, farming, fishing and forestry, and construction and extraction occupations.

These findings indicate that deaths influenced by occupational heat exposure may exceed workplace-based surveillance estimates and may inform federal heat safety standards.

https://ja.ma/4yBwQLG

10/10/2026

Online products marketed as investigational therapies may not contain the ingredients listed on the label and may include unlabeled drugs.

🎙️ In the latest episode of the JAMA Medical News podcast, Kate Schweitzer and Rita Rubin discuss a reported case in which a person who injected a product believed to be retatrutide experienced a potentially fatal esophageal tear after uncontrolled vomiting, and the product was found to contain a large dose of semaglutide instead.

🎧 Listen now:

JAMA Medical News Associate Managing Editor Kate Schweitzer and Lead Senior Staff Writer Rita Rubin discuss “Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain.”

10/09/2026

How useful are "pragmatic" clinical trials for informing real-world decision-making?

In the latest JAMA+ Trials poll, only 10.9% of respondents believed that nearly all trials labeled as "pragmatic" successfully provide useful evidence for real-world decisions. The largest share (34.3%) felt that only a sizeable minority do.

🔖 JAMA+ Trials is a new platform that highlights the implications and innovations of research from across the JAMA Network to advance evidence-based and public .

This October's Trial Theme of the Month focuses on extension studies in , where long-term findings depend on how comparison groups are defined and how attrition and selection bias are handled. Read the latest editorial: https://ja.ma/3UjerEz

📬 Learn more and subscribe to the JAMA+ Trials email newsletter: https://ja.ma/4emygBy

10/09/2026

: Unapproved -1 drugs such as and are being sold on the black market, often at lower costs than approved GLP-1 medications.

But with no regulation, uncertain contents, and safety concerns, these products are no bargain.

This Medical News article discusses the reasons behind the burgeoning black market for 2 unapproved GLP-1 weight loss drugs and the potential risks associated with their use.